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Abst rac t
Introduction: Dendritic cells are crucial for cutaneous immune response. Their role in melanoma progression is 
however a matter of controversy.
Material and methods: The number of dendritic cells within epidermis and in peri- and intratumoral location was 
analyzed using CD207 immunostain in 17 cases of in situ and 25 case of invasive melanoma.
Results: Average peritumoral CD207+ cells count was 22.88 for all cases, 17.94 for in situ lesions and 26.24 for 
invasive cases. Average epidermal CD207+ cells count was 164.47 for all cases, 183.00 for in situ lesions and 150.78 
– for invasive cases. In case of invasive melanomas, peritumoral CD207+ cells count was positively correlated with 
Breslow stage (R = 0.59) mitotic activity within the tumor (R = 0.62). Invasive cases with regression showed higher 
intratumoral and epidermal CD207+ cells count than the ones without (275.00 vs. 95.32 and 173.20 vs. 148.35) but 
lower peritumoral CD207+ cells count (17.60 vs. 27.26). Invasive cases with ulceration showed higher intratumoral 
and peritumoral CD207+ cells count than the ones without ulceration (220.08 vs. 55.67 and 44.17 vs. 9.69).
Conclusions: CD207+ cells play a role in both progression and regression of melanoma but their exact role needs 
further studies.
Key words: malignant melanoma, dendritic cells. 
Introduction
The incidence of cutaneous malignant melanoma 
(CMM) in Europe has steadily increased over the last 
decades [1–3]. In 2012, CMM ranked the seventh among 
the most frequently diagnosed malignancies in the Eu-
ropean Union, constituting 3% of all new cancer cases 
(excluding non-melanoma skin cancers) [4]. Moreover, 
in many EU countries the mortality of CMM has been 
continuously increasing [5] and despite developments in 
melanoma treatment, including BRAF or MEK inhibitors 
as well as anti-CTLA4 monoclonal antibodies [6, 7], cli-
nicians are still powerless in the most advanced cases. 
Consequently, there is still much to be discovered and 
scientists should go further in searching for new prog-
nostic, predictive and therapeutic tools.
In recent years, many authors have demonstrated 
that cancer development and progression is, to some 
extent, controlled by the host’s immune system [8–11], 
which suggests that immunological biomarkers might be 
good indicators of patient’s outcome. As CMM is consid-
ered to be a highly immunogenic tumour [12], the utilisa-
tion of immune cells as prognostic determinants seems 
to represent a very promising approach. Recently, there 
has also been a growing interest in therapeutic potential 
of immune cell-based vaccines against various human 
malignancies [13–16], including CMM [17, 18]. Especially 
dendritic cells (DCs) have been widely investigated, since 
they are believed to be capable of inducing tumour-spe-
cific immunity [19] and, thus, could be used as prognostic 
biomarkers as well as potential therapeutic targets. 
Dendritic cells are the most potent, highly specialised 
antigen-presenting cells (APCs), which links innate and 
adaptive immunity. The DCs constitute a complex system 
of cells found in peripheral tissues as well as immuno-
logical organs, and their presence was also documented 
in a vast range of human malignant tumours [20–25]. 
Response to cancer cells involves the capture of foreign 
antigens by immature DC subsets, their entailing matu-
ration, migration to the lymph nodes and presentation of 
antigen peptides to T cells via major histocompatibility 
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complex (MHC) molecules. However, depending on the 
biological context, DCs can either boost an effective host 
reaction to cancer cells or maintain local tissue tolerance 
that facilitates tumour growth [26, 27]. Distinct DC sub-
types, each having a different phenotype, location and 
function can be identified on the basis of cell surface 
markers and intracellular molecules. The normal human 
skin contains epidermal Langerhans cells (LCs) and der-
mal DCs, while under pathological conditions, plasma-
cytoid as well as inflammatory dendritic epidermal cells 
happen to be detected [28].
Despite many studies on the issue of dendritic cells 
in various cancers, the underlying tumour-host interac-
tions involving certain subsets has not yet been clearly 
elucidated, which prevents the translation of these im-
mune factors into clinical use. Additionally, in the light of 
the importance of DCs, there is a very limited number of 
studies investigating the correlation between their den-
sity and histological characteristics of CMM [29–31]. 
Aim
The objective of the present study was to evaluate 
the infiltration of DCs expressing CD207/langerin, which 
is a C-type lectin displaying mannose-binding specific-
ity, involved in ligand internalisation [32]. The study was 
conducted on a subset of 42 cases, which were obtained 
from patients diagnosed with melanoma in situ or invasive 
malignant melanoma of the skin. The number of DCs was 
analysed in relation to a degree of CMM progression and 
spatial location of DC infiltration (intratumoral, peritumor-
al, epidermal). Evaluation of these parameters might be 
helpful in explaining the prognostic and predictive value 
of DCs in the progression of CMM as well as their potential 
implementation in immunotherapeutical protocols. 
Material and methods
Material
We used cutaneous tissue samples excised from 42 pa- 
tients who were diagnosed with melanoma in situ or 
invasive cutaneous melanoma of the skin between 
2009 and 2013. The paraffin-embedded samples were 
obtained from the archives of the Department of Patho-
morphology, while data concerning the subtype of lesion, 
melanoma stage (described using Breslow depth), pres-
ence of ulceration, mitotic activity (counted per mm2) 
and tumour regression features were collected from the 
database of the Department. 
Immunohistochemistry
Immunohistochemistry was performed using the 
anti-human CD207 (Langerin) monoclonal antibody 
(clone 12D6, Novocastra, Leica Biosystems, Germany), 
dilution 1 : 100, incubation time 60 min. Cutaneous tis-
sue samples were stained manually and processed ac-
cording to the protocol used on a routine basis in the 
laboratory of the Department of Pathomorphology. The 
selected paraffin-embedded tissue blocks were cut into 
4 μm thick sections, mounted on SuperFrost glass slides 
(ThermoScientific, USA) and dried in an incubator for 
12 h in 34°C. The obtained slides were deparaffinized, 
dehydrated and then incubated in 3% H
2
O
2
 solution for 
10 min to block endogenous peroxidase activity. Antigen 
retrieval was performed by immersing the slides in ci-
trate buffer (pH 6.0; 0.01 M) and subjecting them to 97°C 
in a water bath for 40 min. Polyclonal secondary antibod-
ies conjugated to horseradish peroxidase (Ultra Vision 
Quanto Detection System, Lab Vision, ThermoScientific, 
USA), using DAB (3,3’-diaminobenzidine) as chromogen, 
were applied to visualize the obtained antigen-antibody 
complexes. Cell nuclei were stained with hematoxylin to 
enhance contrast in tissue sections.
Evaluation of immunostaining
For each case quantitative assessment of CD207/
langerin-positive cells was performed under light micros-
copy. The positively stained cells (brown membranous 
staining) were counted at 400× magnification. For evalu-
ation of intratumoral, peritumoral and intraepidermal 
cells, the CD207/langerin-positive cells were counted in 
tumour mass, along the tumour border and in overlying 
epidermis, respectively, within the whole section; then 
the cell count was recalculated per mm2 of tissue (de-
pending on the number of investigated fields). The ob-
tained results were entered into an Excel spreadsheet 
(Microsoft Corporation, USA). 
Statistical analysis
Statistical data analysis was performed using Statis-
tica 10 software (StatSoft, USA). The difference between 
the number of CD207/langerin-positive intratumoral, 
peritumoral or intraepidermal dendritic cells and type 
of lesion (invasive vs. in situ) were evaluated by using 
the Mann-Whitney U-test. Spearman rank and gamma 
correlation tests were performed to assess correlations 
between the numbers of CD207/langerin-positive cells 
(intratumoral, peritumoral and intraepidermal) and 
tumour stage (Breslow depth), presence of ulceration, 
mitotic activity and regression features. To evaluate the 
relationships between the content of CD207/langerin-
positive cells and type of lesion, presence of ulceration or 
features of tumour regression, the t-test was performed. 
P-values < 0.05 were considered significant. 
Results
Among 42 cases investigated in our study, 25 (59.5%) 
were diagnosed as invasive melanoma and 17 (40.5%) as 
melanoma in situ.
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For all cases, average peritumoral CD207/langerin-
positive cell count was 22.88 (SD = 28.15) and average 
epidermal CD207/langerin-positive cell count was 164.47 
(SD = 101.15) (Figures 1 and 2).
There were statistically significant correlations be-
tween the number of peritumoral CD207/langerin-posi-
tive cells and Breslow depth (R = 0.60; p = 0.002), mitotic 
activity (R = 0.62; p = 0.001) as well as the presence of 
ulceration (R = 0.58; p = 0.002) in invasive melanoma 
cases. There was a significantly (p = 0.002) higher num-
ber of peritumoral CD207/langerin-positive cells in ul-
cerated invasive melanoma samples (mean: 44.17, SD = 
35.22) in comparison with invasive melanomas without 
ulceration (mean: 9.69, SD = 9.40).
There was no statistically significant (p > 0.05) dif-
ference in peritumoral or intraepidermal CD207/lan-
gerin-positive cell count between invasive and in situ 
melanoma groups. Nonetheless, it is noteworthy that we 
observed a higher number of CD207/langerin-positive 
cells in the peritumoral area of invasive (mean: 26.24, SD 
= 30.36) than of in situ lesions (mean: 17.94, SD = 24.59). 
Contrary to the above results, the number of intraepider-
mal CD207/langerin-positive cells in invasive melanomas 
was lower (mean: 150.78, SD = 114.18) than in in situ le-
sions (mean: 183.00, SD = 79.85) (Figures 3 and 4).
Among invasive melanomas, the average number 
of intratumoral CD207/langerin-positive cells (mean: 
275.00, SD = 483.84) and intraepidermal cells (mean: 
173.20, SD = 156.57) was higher in tumours with regres-
Figure 1. Density of langerin-positive cells in the epidermal 
compartment
Figure 2. Density of langerin-positive cells in the peritu-
moral area
Figure 3. Numerous langerin-positive cells within epidermis 
in case of in situ melanoma
Figure 4. Langerin-positive cells at the tumour border in 
case of invasive melanoma
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sion than in tumours without regression (mean: 95.32, 
SD = 134.34 – for intratumoral, mean: 148.35, SD = 106.41 
– for intraepidermal) (Figures 5 and 6).
By contrast, the peritumoral CD207/langerin-positive 
cell count was lower in invasive melanomas with regres-
sion (mean: 17.60, SD = 35.05) than in cases without re-
gression (mean: 27.26, SD = 30.05). However, for all cases 
the differences were not statistically significant.
Discussion
Langerin (CD207) is a C-type lectin, binding glycosyl-
ated ligands in a calcium-dependent manner, and has 
many roles, such as in cell adhesion, endocytosis, natural 
killer-cell target recognition and dendritic-cell activation 
[33]. So far, it was generally assumed that Langerhans 
cells are the only cells expressing langerin [32, 34, 35], but 
now there is a growing body of evidence indicating that 
langerin expression is not confined to LCs exclusively as 
it is also found in dermal DCs [36–39] and other organs, 
such as lungs, liver, spleen and lymph nodes [36, 40]. In 
mouse skin, the population of DCs comprises CD207/
langerin-positive LCs, forming a network in epidermis, 
as well as CD207/langerin-positive and CD207/langerin-
negative DC subsets residing in the dermis [37–39]. As 
far as human dermis is concerned, one study confirming 
the existence of CD207/langerin-positive dermal DCs has 
been published recently [36]. One of the main reasons 
why previous studies have evaluated dermis as langer-
in-negative compartment [32, 41] might be the fact that 
CD207/langerin-positive DCs found in the steady state 
in dermis are rare, and if they were ever noticed, they 
were regarded as LCs in transit through the dermis on 
their way to the lymph nodes [39, 42]. In addition, some 
in vitro studies have demonstrated that the production 
of langerin in human progenitor cells and monocytes can 
be induced by a variety of factors, such as transforming 
growth factor β (TGF-β), granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF), tumor necrosis factor α 
(TNF-α) and bone morphogenetic protein 7 (BMP7)  [43–
45], which also supports the view that langerin might be 
expressed by distinct dermal DC subtype, not related to 
epidermal LCs. Although these observations need to be 
clarified, they have to be considered in the interpretation 
of the presented results. 
Tumour thickness, mitotic rate and ulceration are the 
most dominant prognostic factors for clinical outcome of 
malignant melanoma [46]. Our study revealed a statisti-
cally significant positive correlation between each recog-
nised prognostic feature and the infiltration of CD207/
langerin-positive DCs in the peritumoral area of invasive 
CMM. Since the increased tumour thickness, higher mi-
totic rate and presence of ulceration are indicators of 
decline in survival rates, our findings may suggest that 
a higher number of CD207/langerin-positive DCs at the 
border of the tumour favours disease progression and is 
associated with worse prognosis. This conclusion would 
be consistent with the observation that CD207/langerin-
expressing dendritic cells in human tissues are related 
to immature CD1a/CD1c-positive cells [36], and thus 
presumably play a role in tolerance rather than in immu-
nity, as immature DCs are unable to effectively present 
processed foreign antigens to T cells. It is, however, still 
unknown whether the higher infiltration of immature 
DCs in peritumoral area is mostly the consequence of 
their impaired maturation or is solely caused by the ex-
cessive migration to the pathologically altered site, and 
the progression of the disease should be rather ascribed 
to the inadequate functioning of mature dendritic cells. 
If a case of massive migration was considered to be more 
probable, it would be recommended to investigate local 
factors, which may possibly support the recruitment of 
Figure 5. Density of intratumoral langerin-positive cells in 
invasive melanomas with and without regression
Figure 6. Density of epidermal langerin-positive cells in in-
vasive melanomas with and without regression
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CD207/langerin-positive dendritic cells in CMM, as e.g. 
CCL20 chemokine was proposed to be crucial for CD207/
langerin-positive DCs migration to EBV-associated tu-
mours [47]. There are also substantial ambiguities re-
sulting from the lack of sufficient information about the 
pathophysiological processes involved in CMM progres-
sion, which makes the speculation about the role of DCs 
in the disease progression even more complicated; for 
instance, very little is known about the underlying bio-
logical mechanisms of CMM ulceration [48]. Literature 
data concerning the significance of CD207/langerin-
positive cells in CMM are very scarce and findings vary 
considerably between papers. In a study conducted on 
185 primary melanomas, Gerber et al. did not show any 
significant influence of CD207/langerin expression on 
the clinical outcome [49]. Moreover, given the observa-
tion that in human tissues CD207/langerin-positive DCs 
were found to be closely related to CD1a-positive sub-
sets, as described above, it is justified to mention that 
infiltration of CD1a-positive DC peritumoral area of CMM 
was observed to correlate positively with decreased tu-
mour thickness [50], which might be interpreted as be-
ing contrary to our findings. In addition, we have found 
a significant inverse association between the number of 
CD207/langerin-positive DCs and the presence of mela-
noma regression features, whose presence is tradition-
ally regarded as an indicator of poor prognosis. Nonethe-
less, the impact of tumour regression is still unclear, as 
some studies revealed that this feature does not have 
any independent prognostic value [51], while others dem-
onstrated a higher metastatic rate in CMMs with exten-
sive regression [52]. Taken together, there are still many 
unresolved questions, which prevents us from drawing 
valid conclusions on whether CD207/langerin-positive 
cells play any specific role in inducing or regulating an 
immune response in the progression of CMM, and thus 
their correlations with established prognostic factors 
must be interpreted with caution. 
We found a substantially higher average number of 
intratumoral and epidermal CD207/langerin-positive 
DCs in invasive melanomas with regression. With regard 
to the differences in the spatial distribution of CD207/
langerin-positive DCs we can conclude that despite the 
enhanced intranestal recruitment of DCs in more ad-
vanced stages, the immune interactions are ineffective 
to elicit an appropriate antitumor response. It is sug-
gested that some melanoma-derived factors, such as 
TGF-β and interleukin 10 (IL-10), found in melanoma cell 
nests, might adversely influence migration of dendritic 
cells, their differentiation and function [53–55]. Neagu 
et al. demonstrated that the presence of LCs within mel-
anoma tumour mass correlates with the Breslow index 
but not with ulceration; yet the general intratumoral LC 
content was described to be rather scarce [8]. Regard-
ing other human malignancies, the infiltration of CD207/
langerin-positive DCs was also observed in Hodgkin 
lymphoma, nasopharyngeal carcinoma, oral squamous 
cell carcinoma and breast cancer [47, 56, 57]. However, 
in the latter case the infiltration by immature CD207/
langerin-positive DCs was found in only one-third of the 
breast cancer tissues and did not correlate with clinico-
pathological data. In our cohort of melanoma samples, 
we have also observed a higher intratumoral langerin 
expression compared to the peritumoral area in invasive 
CMM. Assuming again that langerin is mostly present on 
immature dendritic cells and is related to CD1a-positive 
subsets, this observation is in agreement with the results 
obtained by other authors investigating various human 
malignancies, as it is generally suggested that immature 
dendritic cells are located within tumour nests, while 
mature subsets reside in peritumoral compartment [29, 
58]. Conversely, the intraepidermal infiltration of CD207/
langerin-positive DCs was more pronounced in non-in-
vasive lesions of our study, which is in concert with the 
findings of other authors showing a reduced number of 
intraepidermal DCs in invasive melanoma tissues [53, 
59]. The possible explanations of the depletion of DCs in 
the epidermis during the evolution of CMM include ne-
crosis, regression and scarring in more advanced stages 
of the tumour [53] as well as the presence of basement 
membrane along with the lack of epidermal own blood 
vessels. We represent the view that in order to better un-
derstand the role of CD207/langerin-positive DCs in CMM 
evolution, the issue of their uneven distribution between 
invasive and non-invasive melanomas should be revis-
ited on a larger sample of cases.
Conclusions
Our results may shed light on the relevance of 
CD207/langerin-positive DCs at different stages of CMM 
and clarify some of their associations with traditional 
risk prediction based on histopathological characteris-
tics. In interpreting these findings we should, however, 
remember that the evaluation of density and location 
of DCs relied on staining for CD207/langerin exclusively, 
thus, we were unable to analyse the whole spectrum of 
DC subsets and their interactions with other immune 
cells involved in melanoma carcinogenesis. In order to 
draw a complete picture of the role of DCs in melanoma 
control, the thorough analysis of the dendritic cell family, 
including numerous markers, as well as other presum-
ably contributing microenvironmental factors, such as 
cytokines, is required. Moreover, the inclusion of mela-
noma metastases might also bring some added value to 
the evaluation of DCs in progression of the disease. In 
addition, we should also bear in mind that melanoma 
patient’s survival can vary significantly among individu-
als within the same tumour stage and widely accepted 
classifications (e.g. Breslow depth, TNM) may not utterly 
correspond with the ongoing immunological processes. 
Thus, only a prospective analysis of the patient’s clinical 
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outcome will allow us to better understand the predictive 
and prognostic significance of CD207/langerin-positive 
tumour-infiltrating DCs. Although the role of DCs infil-
trating CMM demands further elucidation, we believe 
that our study gives a valuable insight into the role of 
CD207/langerin-positive DCs in the progression of CMM 
and might prove useful in incorporating immune scoring 
in clinical settings. 
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